

CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No. ANG/23-24/BSE -129

Date 14-08-2023

To

Department of Corporate Services,
BSE Limited
P J Towers, Dalal Street,
Mumbai- 400001

Ref: BSE Security Code 540694

Sub: Outcome of Board Meeting pursuant to Reg. 30 of SEBI (Listing Obligation and Disclosure Requirements), Regulation, 2015.

Dear Sir/Madam,

With reference to the cited subject matter, we would like to inform you that the Board of Directors of the Company at its meeting held on today i.e., 14th August, 2023, have inter- alia, transacted the following item(s) of the Agenda:

1. Approved the Standalone and Consolidated Un-audited Financial Result along with the Limited Review Report for the first quarter ended as at 30th June, 2023 and a copy of the same is enclosed
2. Approved the appointment of Secretarial Auditor – M/s Anjum Goyal & Associates, Practicing Company Secretaries for FY 2023-24

The meeting commenced at 04:30 PM and concluded at ~~05:30~~ 05:30 PM

Please take the above intimation on your records.

Thanking You
Yours' faithfully

For ANG Lifesciences India Limited


Renu Kaur
Company Secretary
M no A62402





Raman Wadhwa & Co.

CHARTERED ACCOUNTANT

43, 3rd Floor, Nehru Shopping Complex, Lawrence Road, Amritsar.
E-mail: ishantsharma2187@yahoo.com

Ref. No.

Dated. 14/08/23

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To

The Board of Directors of
ANG Lifesciences India Limited

1. We have reviewed the accompanying statement of Unaudited Standalone Financial Results of ANG Lifesciences India Limited ("the Company") for the quarter ended 30th June, 2023 ("the statement") attached herewith being submitted by the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 as amended, including relevant circulars issued by the SEBI from time to time.
2. This Statement which is the responsibility of the Holding Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurements principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 as amended read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
3. We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Raman Wadhwa & Co.
Chartered Accountants

(Ishant Sharma)
Partner

Reg. no. 012036N

M. No. 527055

UDIN: 23527055 BURPALH140

Date: 14.08.2023

Place: Amritsar



Raman Wadhwa & Co.

CHARTERED ACCOUNTANT

43, 3rd Floor, Nehru Shopping Complex, Lawrence Road, Amritsar.
E-mail: ishantsharma2187@yahoo.com

Ref. No.

Dated. 14/08/23

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To

The Board of Directors of
ANG Lifesciences India Limited

1. We have reviewed the accompanying statement of Unaudited Consolidated Financial Results of ANG Lifesciences India Limited ("Holding Company") and its Wholly owned subsidiary (the Holding and its Wholly owned subsidiary together referred to as "the Group", (refer point no. 5 in this Statement] for the quarter ended 30th June, 2023 ("the statement") attached herewith being submitted by the Holding Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 as amended ("the Listing Regulations") including relevant circulars issued by the SEBI from time to time.
2. This statement which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors has been prepared in accordance with the recognition and measurements principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 as amended read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
3. We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. We also performed procedures in accordance with the Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, to the extent applicable.
5. The Statement includes the result of the following entities:-
Mansa Print & Publishers Limited
6. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited consolidated financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Raman Wadhwa & Co.
Chartered Accountants

(Ishant Sharma)
Partner

Reg. no. 012036N


M. No. 527055

UDIN: 23527055 BWRPAK 2858

Date: 14.08.2023

Place: Amritsar

CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No.

Date.....

Statement of standalone unaudited results for the quarter ended 30 June 2023

(₹ in lakhs except per share data)

Particulars	Quarter ended 30 June 2023	Quarter ended 31 March 2023	Quarter ended 30 June 2022	Year ended 31 March 2023
	(Unaudited)	refer note 4 (Audited)	(Unaudited)	(Audited)
I Revenue from operations	5,060.80	3,188.36	7,155.63	20,700.55
II Other income	34.32	919.62	12.34	984.24
III Total revenue (I+II)	5,095.12	4,107.98	7,167.97	21,684.79
IV Expenses				
Cost of materials consumed	3,026.04	3,297.37	4,848.69	15,112.43
Changes in inventories of finished goods and work-in-progress	335.99	(80.79)	(148.50)	(422.17)
Employee benefits expense	473.71	480.37	548.64	2,027.43
Finance costs	193.78	111.44	317.45	1,032.43
Depreciation and amortisation expenses	193.63	281.63	188.09	851.63
Other expenses	658.17	650.75	778.75	2,876.11
Total expenses (IV)	4,881.32	4,740.77	6,533.12	21,477.87
V Profit before exceptional items and tax (III-IV)	213.80	(632.79)	634.85	206.92
VI Exceptional items	-	-	-	-
VII Profit before tax (V-VI)	213.80	(632.79)	634.85	206.92
Tax expense				
(1) Current tax	81.88	-114.86	236.31	210.87
(2) Deferred tax	-27.76	(14.90)	64.24	62.27
VIII Total tax expense (1+2)	54.12	(129.76)	300.55	273.14
IX Profit for the period (VII-VIII)	159.68	(503.03)	334.30	(66.22)
X Other comprehensive income:				
Items that will not be reclassified to profit or (loss)	10.81	-17.81	85.60	95.72
Income tax relating to items that will not be reclassified to profit or loss	-2.72	4.48	(21.54)	(24.09)
XI Total comprehensive income (IX+X)	167.77	(516.36)	398.36	5.41
XII Paid-up equity share capital (Face value ₹ 10/- per share)	1,305.83	1,305.83	1,036.66	1,305.83
XIII Other equity				7,247.69
XIV Earnings per equity share (of ₹ 10/- each)				
-Basic and diluted	1.28	(3.95)	3.84	0.04

See accompanying notes to the financial results.



CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No.

Date.....

Statement of consolidated audited results for the quarter ended 30 June 2023

(₹ in lakhs except per share data)

Particulars	Quarter ended 30 June 2023	Quarter ended 31 March 2023	Quarter ended 30 June 2022	Year ended 31 March 2023
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
I Revenue from operations	5,646.25	3,943.69	7,370.75	21,989.11
II Other income	31.65	923.27	8.83	972.35
III Total revenue (I+II)	5,677.90	4,866.96	7,379.58	22,961.46
IV Expenses				
Cost of materials consumed	3,413.88	3,871.08	4,749.41	15,608.02
Changes in inventories of finished goods and work-in-progress	281.74	(200.16)	(44.66)	(549.05)
Employee benefits expense	576.48	584.62	619.75	2,397.07
Finance costs	231.41	165.41	344.47	1,187.87
Depreciation and amortisation expenses	218.81	302.63	208.96	935.35
Other expenses	719.43	716.26	844.91	3,119.70
Total expenses (IV)	5,441.75	5,439.84	6,722.84	22,698.96
V Profit before exceptional items and tax (III-IV)	236.15	(572.88)	656.74	262.50
VI Exceptional items	-	-	-	-
VII Profit before tax (V-VI)	236.15	(572.88)	656.74	262.50
Tax expense				
(1) Current tax	81.88	(114.86)	236.31	210.87
(2) Deferred tax	(20.94)	2.87	71.04	77.85
VIII Total tax expense (1+2)	60.94	(111.97)	307.35	288.72
IX Profit for the period (VII-VIII)	175.21	(460.91)	349.39	(26.22)
X Other comprehensive income:				
Items that will not be reclassified to profit or (loss)	11.95	(17.62)	85.94	97.39
Income tax relating to items that will not be reclassified to profit or loss	(3.01)	4.43	(21.63)	(24.51)
XI Total comprehensive income (IX+X)	184.15	(474.09)	413.70	46.66
XII Paid-up equity share capital (Face value ₹ 10/- per share)	1,305.83	1,305.83	1,036.66	1,305.83
XIII Other equity				7,315.94
XIV Earnings per equity share (of ₹ 10/- each)				
a) Basic	1.41	(3.63)	3.99	0.36
b) Diluted	1.41	(3.63)	3.99	0.36

See accompanying notes to the financial results.



CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No.

Date.....

As per Ind-AS 108, Operating Segments have been defined and presented based on the regular review by the Company's Chief Operating Decision Maker to assess the performance of each segment and to make decision about allocation of resources. The accounting principles used in the preparation of the consolidated unaudited financial results are consistently applied to record revenue and expenditure in individual segments. Accordingly, the consolidated unaudited segment wise revenue, results, assets, and liabilities is as follows :

S.No.	Particulars	(₹ in lacs)			
		Quarter ended			Year ended
		30 June	31 March	30 June	31 March
		2023	2023	2022	2023
		(Audited)	(Unaudited)	(Audited)	(Audited)
1	Segment revenue				
	a) Pharmaceuticals	5,060.80	3,188.36	7,155.63	20,700.55
	b) Printing and packagings	679.39	724.44	985.44	2,420.51
	Total	5,740.19	3,912.80	8,141.07	23,121.06
	Less: Inter segment revenue	93.94	(30.89)	770.31	1,131.95
	Revenue from operations	5,646.25	3,943.69	7,370.76	21,989.11
2	Segment results (profit before tax and finance cost from each segment)				
	a) Pharmaceuticals	407.69	(505.36)	950.32	1,239.35
	b) Printing and packagings	63.68	113.11	50.89	226.25
	Total	471.37	-392.25	1,001.21	1,465.60
	Less: Finance costs	235.22	180.63	344.47	1,203.10
	Profit before tax	236.15	-572.88	656.74	262.50
	Particulars			As at 30 June 2023 (Unaudited)	As at 31 March 2023 (Audited)
3	Segment Assets				
	a) Pharmaceuticals			23,358.64	24,448.18
	b) Printing and packagings			3,517.16	3,522.11
	Total Segment assets			26,875.80	27,970.29
4	Segment liabilities				
	a) Pharmaceuticals			15,549.40	16,697.33
	b) Printing and packagings			2,729.71	2,651.71
	Total Segment liabilities			18,279.11	19,349.04



CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No.

Date.....

Notes:

1. ANG Lifesciences India Limited is a public listed company incorporated in India and is in the business of manufacturing and sales of finished pharmaceutical formulations in a dosage form of Dry Powder Injection Vials, Liquid Injections Vials, Ampoules, PFS, Hard Gelatin Capsules, Tablets, Soft Gelatin Capsules, Dry Syrups, Liquid Syrups and Suspension, Lotions etc. ANG's products portfolio comprises of major therapeutic categories such as Antibiotics, Antiviral, Antimalarial, Antiulcer, Carbapenem, Corticosteroid, Penicillin, Beta Lactamase Inhibitor etc.
2. The above financial results for the quarter ended 30 June 2023 have been reviewed by the Audit Committee and approved by the Company's Board of Directors in their respective meetings held on 14 August 2023. The Statutory Auditors of the Company have expressed unmodified opinion on these results.
3. The above results of ANG Life Sciences India Limited ('the Company' or 'the Holding Company') and its subsidiary (the Holding and the subsidiary together referred to as 'the Group') have been prepared with in accordance with the recognition and measurement principles as laid down in Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act 2013 read with rule 3 of the Companies (Indian Accounting Standard) Rules, 2015, Companies (Indian Accounting Standard) Amendment Rules, 2016 and as per the presentation requirements of SEBI Circular CIR/CFD/FAC/62/2016 dated 05 July 2016 and other accounting principles generally accepted in India. Consequently, financial results for the quarter ended 30 June 2023 have been aligned to comply with Ind AS requirements to make them comparable with current periods.
4. Figures for the standalone and consolidated financial results for the quarter ended 31 March 2023 are the balancing audited figures of the full financial year and the published year to date figures upto the third quarter of the year ended 31 March 2023 which were subjected to limited review by the statutory auditors of the Company.
5. These financial results are available on the website of the Company at www.anglifesciences.com and are also available on the website of Bombay Stock Exchange at www.bseindia.com.
6. Previous period figures have been re-grouped/reclassified wherever necessary, to conform to current period's classification.

For and on behalf of the Board of Directors of
ANG Lifesciences India Limited

(Managing Director)

Place: Amritsar

Date: 14 August 2023